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ABSTRACT  
Recently, nanoparticles have become an origin of exploration in the chemistry field due to their unique 
medical uses. The current drug delivery models of nanoparticles often include a metal base with a drug 
conjugated to its surface. However this raises concerns regarding toxicity. A novel approach to solving 
this dilemma is the development of nanosized biocompatible polymer-based micelles, created from PEG-
PCL-PEG triblock polymer, and formed around a drug of choice. The goal is to create a drug carrier 
nanoparticle system that is labile at a specific intracellular pH, without undue toxicity to the cell. This 
creates a drug-loaded nanoparticle that dissociates when exposed to a pH of 5.4, thus releasing the drug 
at the targeted location in the cell, the late endosome. Using polymer micelles as a drug-carrier allows 
scientists to control the destination of the drug, while creating stand-alone units that can be combined to 
reach the desired concentration. The molecules ribavirin, Nile red and 6-azauridine were drug-loaded and 
analyzed to ensure encapsulation then released at a pH of 5.4. The nanoparticles had an average diameter 
before dissociation of 63.44, 84.73 and 55.25 nm respectively. By utilizing this drug delivery system we 
are able to target specific intracellular pH values that are known to occur around landmarks of the cell 
and thus can manipulate drug release accordingly. The drug delivery system that is described in this 
thesis is designed and analyzed for its future potential to target and successfully suppress Flaviviridae 
viruses, such as dengue and Zika virus.  
INDEX WORDS: Nanoparticles, Micelles, Polymer, Biocompatible, Drug carrier, Antiviral, 
Flaviviridae, Virus suppression, Ribavirin, 6-Azauridine 
DESIGN, SYNTHESIS AND APPLICATIONS OF NANOPARTICLES IN SUPPRESSION OF 
MOSQUITO-BORNE FLAVIVIRDAE VIRUSES 
by 
MARIA BLAHOVE 
B.S., Georgia Southern University, 2018
A Thesis Submitted to the Graduate Faculty of Georgia Southern University 
in Partial Fulfillment of the Requirements for the Degree 





























DESIGN, SYNTHESIS AND APPLICATIONS OF NANOPARTICLES IN SUPPRESSION OF 

















 Major Professor:   James Carter  
 Committee:   William Irby 
    Michele McGibony 
    Amanda White 
 
 
Electronic Version Approved:  
































































The author would like to acknowledge the following for their time and assistance; 
Dr. Carter, for being my research advisor and guiding my research in order to achieve my goals.  
My research committee for the hours spent reading my work and making sure I was being pushed to the 
best version I was capable of.  
Dr. White for always being available to talk through any set back that occurred and for training/use of the 
lyophilizer in her lab.  
Dr. McGibony for all the help navigating graduate school.  
Dr. Takas for the instrument training throughout the years.  
Mrs. Ferguson and Mr. Anderson for all the logistical and safety help over the years.  
The other graduate students in no particular order; Nadia Singleton, Hunter Whitetree, Khristal Monroe, 
and Ricardo Belloso for all the morale boosting and help throughout my time as a graduate student. 
My undergraduate research advisor, Dr. Stone for giving me the foundation required to achieve my 






























TABLE OF CONTENTS 
      
      
           Page  
 
ACKNOWLEDGMENTS............................................................................................................................. 3  
LIST OF TABLES..........................................................................................................................................6 
LIST OF FIGURES.......................................................................................................................................7 
CHAPTER 
  1 INTRODUCTION………………………………………………………………………….…....8
  1.1 The Discovery of Viruses..……………………………………………………….........9 
  1.2 Flaviviridae Family of Viruses …………...………………………………….………..9 
  1.3 The Flavivirus Genus……………………………………………………...…………10 
  1.4 Aedes Mosquitoes ……………………………………………………………………11 
  1.5 Zika Virus ……………………………………………………………………………11 
  1.6 Dengue Virus ………………………………………………………………………...12 
 2 NANOPARTICLE DESIGN AND APPROACH ………………………....………….………..13 
  2.1 Introduction of Biodegradable Coblock Polymers ……………………………….…..13 
  2.2 Triblock mPEG-PCL-mPEG Polymer ……………………………………………….14 
  2.3 mPEG-PCL-mPEG Micelles …………………………………………………...........15 
  2.4 Thermal Induced Self-assembly of Polymeric Micelles ……………………………..15 
 3 DRUG-LOADING OF MICELLES…………………………………………………………….17 
 3.1 Introduction to Drug-Loading of Polymeric Micelles…………..………….…………17 
 3.2 Topological Polar Surface Area ………………………………………………….…..18 
   3.3 Introduction of the Antiviral, Ribavirin ……………………………………………..19 
  3.4 Introduction of the Fluorescent Tracking Dye, Nile Red………….………………….20 
  3.5 Introduction of the Antiviral, 6-Azauridine………………………………….……….20 
 4 MATERIALS AND METHODS………………………………………………………...……..21 
  4.1 Synthesis of Triblock polymer, mPEG-PCL-mPEG…………………….....…………21 
  4.2 Synthesis of mPEG-PEC-mPEG Micelles……………………………………………22 
  4.3 Ribavirin Drug-loaded mPEG-PCL-mPEG Micelles………………………………...22 
  4.4 Kinetics Study of Ribavirin-loaded mPEG-PCL-mPEG Micelles …………………..23 
  4.5 Nile Red Drug-loaded mPEG-PCL-mPEG Micelles…………………….…………...23 
  4.6 6-Azauridine Drug-loaded mPEG-PCL-mPEG Micelles…………………………….24 
  4.7 Drug Release Study of 6-Azauridine Drug-loaded mPEG-PCL-mPEG Micelles…….24 
  4.8 6-Azauridine Standard……………………………………………………………......24 
  5 RESULTS……………………………………………………………………………………….25 
  5.1 Characterization of the Triblock, mPEG-PCL-mPEG……………………….……….25 
  5.2 Characterization of Ribavirin-loaded mPEG-PCL-mPEG Micelles……………….…26 
  5.3 Kinetics Study of Ribavirin-loaded mPEG-PCL-mPEG Micelles…………………...28 
  5.4 Characterization of Nile Red-Loaded mPEG-PCL-mPEG Micelles …………….…...31 
  5.5 Characterization of 6-Azauridine-Loaded mPEG-PCL-mPEG Micelles…………….32 
  5.6 Drug Release Study of 6-Azauridine-loaded mPEG-PCL-mPEG Micelles………….33 
 6 DISCUSSION …………………………………………………………………….……...……..35 








LIST OF TABLES 
 
                                                                                                                                    Page  
 
Table 1: The cellular micro pH values of the life cycle of the Flaviviridae family of viruses  …..10  








































LIST OF FIGURES 
 
 Page  
 
Figure 1: Life cycle of a Flaviviridae family of viruses…………………………………………......9 
Figure 2: Diagram of a typical Flavivirus virus ………………………………………………….....10 
Figure 3: The 2017 CDC estimates of Aedes mosquitoes in the United States………………………11  
Figure 4: General scheme of an ABA triblock formation …………………………………………..14  
Figure 5: The reaction of formation for the AB diblock…………………………………………….14 
Figure 6: The reaction of coupling the AB diblock to the A monomer……………………………. .14 
Figure 7: ABA triblock polymer based, drug-loaded micelles……………………………………...15 
Figure 8: General scheme of thermal induced self-assembly and drug loading…………………….18 
Figure 9: Comparison of determination of a molecules TPSA to PSA………………………….…..19 
Figure 10: Structure of the antiviral, ribavirin……………………………………………………....19 
Figure 11: Structure of the fluorescent probe, Nile red…………………………………….………..20 
Figure 12: Structure of the antiviral, 6-Azauridine.......…………………...……………….………..20 
Figure 13: FTIR analysis of mPEG-OH and mPEG-PCL-mPEG…………………………………..25 
Figure 14: UV-visual spectroscopy of ribavirin loaded and blank triblock micelles……………….26 
Figure 15: Zeta potential of the micelles…………………………………………………………….27 
Figure 16: Average diameter of the micelles determined by dynamic light scattering……………..27 
Figure 17: UV-Visual spectroscopy of varying concentrations of ribavirin in DI water…………...28 
Figure 18: Standard of ribavirin at 270nm……………………………………………………….....29 
Figure 19: UV-visual spectra of kinetics study…………………………………………………......29 
Figure 20: Average diameter of micelles in kinetics study………………………………….……...30 
Figure 21: UV-visual spectroscopy of the Nile red loaded and blank, triblock  micelles…………...31 
Figure 22: Average diameter of Nile-red loaded micelles……………………………………….…31 
Figure 23: UV-visual spectrum of 6-azauridine-loaded mPEG-PCL-mPEG micelles………….….32 
Figure 24: Average diameter of 6-azauridine-loaded micelles.……………………………….……32 
Figure 25: UV-visual spectra's of 6-azauridine-loaded and dissociated micelles…………….…….33 
Figure 26: Average Diameter of 6-azauridine-loaded micelles after dissociation…………….……33 
Figure 27: UV-Visual spectroscopy of varying concentrations of 6-azauridine in DI water….……34 


















1.1 The Discovery of Viruses 
Ever since the birth of the germ theory of disease by Ignaz Semmelweis and confirmation by 
Louis Pasteur, mankind has sought out methods to combat infectious agents that were far too small to be 
observed with human eyes.1 At the time, scientists all over the world were noting that some disease 
causing agents were too small to be caught by traditional filters and therefore ideas spread that maybe this 
was not a bacteria.1 When Louis Pasteur started to prove to the world that microbes could cause diseases, 
scientists’ and doctors’ perceived knowledge on the subject started to diminish, therefore sparking the 
desire to discover a new world of organisms. Unfortunately, during Pasteur’s day the term “virus” came 
from the Latin word for a slimy liquid or poison and often was used interchangeably for any infectious 
agent that caused disease. This often led to bacteria being grouped together with what today would be 
classified as a virus. Not too long after the acceptance of infectious agents being able to pass through the 
smallest filters available did scientists begin to solely refer to these pesky infectious agents as “viruses”. It 
was clear that these pathogens could cause problems with very little knowledge on the topic. However, it 
was unclear at times how they should deal with them.   
With a seemingly endless world to discover ahead it did not take long for the first human virus to 
be discovered in 1901 by a team in Cuba. Major Walter Reed, a U.S. Army physician and the team of 
Cuban doctors were able to confirm that a virus to which was referred to as “yellow fever virus” was 
indeed the cause of the disease, yellow fever.1 The team was also able to identify the host from which 
humans were contracting the virus, mosquitoes.1  This was a promising start and the world took notice as 
the team from Cuba combated the outbreak of yellow fever that was plaguing the U.S. army.  
Since the discovery of viruses in the late 19th century, a lot has been learned about their unique 
nature. Viruses are historically characterized by their size along with their biochemical properties such as 
protein composition and genetic information.1 Viruses are also noted as the smallest of all self-replicating 
organisms.1 The basic components of viruses include a small segment of nucleic acid that is encapsulated 
in a simple protein shell. Viruses are reliant on a host in order to carry out tasks such as amplification, 
making viruses unique in their lack of metabolism. Because of this there is debate on the topic of viruses 
being categorized as “living”. However, it should not be mistaken that the inherent simplicity of viruses 
infers a simple group of pathogens.     
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Since virology as a discipline is a relatively new field of study and is roughly a century old, early 
taxonomy was focused around the diseases caused by viruses. This led to groupings based on concepts 
like animal based viruses and human based viruses. Increasing detection of infectious agents and their 
identification made it clear a new classification system needed to be created that could adequately 
distinguish the various viruses. In 1966, the International Committee on Nomenclature of Viruses (ICNV) 
was established and was tasked with the development of a classification and naming system of the 
viruses.1 Such a diverse set of viruses made classification based on a single characteristic problematic and 
thus the ICNV settled for a polythetic system based on viruses sharing several characteristics. However, 
viruses were not required to share all of the characteristics. The classifications ultimately led to the vast 
modern day virus taxonomy that is still being adjusted today.1 
1.2 Flaviviridae Family of Viruses  
Viruses that infect humans were characterized into 21 families. The first human virus discovered 
was utilized as the representative for its own family, Flaviviridae. Flaviviridae came from the Latin word 
flavus, or yellow, and paid homage to the yellow fever virus first proved in Cuba.1 This virus family was 
centered around positive-stranded RNA viruses and members were classified into three superfamilies: 
Flavivirus, Pestivirus and Hepacivirus. A fourth 
genus, Pegivirus, has recently been proposed to 
encompass unclassified viruses that are closest 
to Flaviviridae.1 It is predicted with time, 
discovery, and greater understanding of viruses 
that new classifications along with 
reclassifications will occur as the field evolves 
with technology. 
Flaviviridae are organized around a few 
key common features in both viral particle 
characteristics and replication life cycle. As 
mentioned above, the positive-stranded RNA 
viruses that compose the Flaviviridae family fall 
into four superfamilies, based on distinctive 
similarities. The family as a whole is 
typically characterized by their lipid bilayer which consists of two or more envelope (E) glycoprotein 
subunits surrounding the nucleocapsid. The nucleocapsid is comprised of the single-stranded, positive-
sense RNA genome complex that has multiple, basic capsid (C)  proteins.  
Figure 1. Life cycle of the Flaviviridae family of viruses.1  
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General replication of the viruses in the Flaviviridae family begins with receptor-mediated 
endocytosis. Figure 1 showcases the life cycle of the Flaviviridae family where key steps are dictated by 
pH in Table 1.1,2,3 Early fusion of the virion envelope with the cellular membrane occurs, through fusion 
due to the low pH of the endosome. After the acid-catalyzed fusion occurs the nucleocapsid starts to 
dissociate thus releasing the RNA genome into the cytoplasm. The released RNA finds its way to the 
endoplasmic reticulum (ER) where membrane bound RNA replication occurs. It is in the ER where the 
positive-stranded RNA template is transformed into RNA for further replication. Some positive strands 
can be assembled into virions and are transported to the trans-Golgi to mature before undergoing 
intracellular budding and exocytosis to be released from the cell. The RNA genome has three major roles 
during the replication life cycle: 1) serve as the messenger RNA (mRNA) for translation of viral proteins, 
2) serve as a template in RNA replication, and 3) act as the genetic material packaged within the new
virus particles for further infection of naïve cells.
Step in Life Cycle Micro pH 
Acid-catalyzed fusion of virus and endosome 5.5 
Translation, replication and assembly in the ER 7.2 
Maturing of the virions in the Trans-Golgi network 6.7 and 6.0 
Intracellular budding and exocytosis 5.7 
1.3 The Flavivirus Genus 
The Flavivirus genus of the family, Flaviviridae is home to more than 50 species of pathogens, of 
which the majority are arthropod-borne human pathogens.1 Viruses in the family are responsible for a 
variety of diseases to include fever, encephalitis, and hemorrhagic fevers.1,4-7 In recent years there has 
been a global concern over some of the viruses in 
this genus to include dengue virus (DENV), West 
Nile virus (WNV) and Zika virus (ZIKV).1,4-7 The 
infectious particles tend to be roughly spherical in 
nature and can be characterized as approximately 50 
nm in diameter.1 These viral particles consist of a 
shell that is made up of two viral proteins 
surrounding a capsid protein which store the viral 
RNA of the virus (Figure 2).1,5  
Table 1. The cellular micro pH values regulating the life cycle of the Flaviviridae family of 
viruses.3
Figure 2. Diagram of a typical Flavivirus virus 




1.4 Aedes Mosquitoes 
 The Aedes genus of mosquitoes is 
home to two specific mosquito types found in 
the United States: Aedes albopictus and Aedes 
aegypti, which are commonly the vial vector 
for Flaviviridae virus infections. It is the 
female mosquitoes that transmit the virus 
through biting the host, and a single bite can be 
responsible for transmitting more than one 
virus. Aedes mosquitoes are traditionally found 
in tropical or subtropical locations with 
historically noted epidemics of disease 
occurring as early as the 17th in countries like 
Africa, Americas and parts of Europe however 
in recent years with the increase in urban travel 
coupled with rising global temperatures the 
mosquitoes preferred climate has 
broadened.1,4,6,8 Aedes albopictus mosquitoes 
tend to flourish in a broader temperature range 
and blood feed on both animals and humans 
which drops the likelihood of spreading viruses 
transmittable to humans.8 The Aedes aegypti 
thrive in warmer climates but prefer to blood feed on humans and therefore are more likely to spread 
human transmittable viruses such as dengue virus, West Nile virus, Zika virus, etc.8 The Center for 
Disease Control and Prevention (CDC) estimated in 2017, using county-level and historical records that, 
Aedes mosquitoes could survive and reproduce in the  majority of the southeastern portion of the United 
States of America (Figure 3).8 While the CDC only investigated whether or not the mosquitoes could live 
and reproduce, it did not indicate if the Aedes mosquitoes had become established in the area. It was the 
U.S. army that confirmed the presence of Aedes mosquitoes in Georgia as early as 2016, specifically the 
Aedes aegypti.6  
 
1.5 Zika Virus 
 Zika virus (ZIKV) is an emergent, mosquito-borne virus of the Flaviviridae family that utilizes 
the Ades mosquitoes for transmittance.4,5 The virus is spread primarily through the bite of a female Ades 
Figure 3. The 2017 CDC estimate of Aedes 




mosquitoes which is infected with ZIKV however vertical transmission can occur between a pregnant 
woman and her fetus.4  The virus was first isolated in a sentinel rhesus monkey in the Zika forest of 
Uganda in 1947 and was later detected in the first human in 1952.4,5,6 The majority of cases are either 
asymptomatic or mild and include symptoms such as: fevers, rash, conjunctivitis, muscle/joint pain, 
malaise and headaches and therefore are underrepresented. However some cases become severe cases and 
present with symptoms consistent with Guillain-Barré syndrome or congenital malformations on infants 
to include club feet and microcephaly.4,7  
 Clinical assessment and treatment of Zika infected humans is wildly dependent on the person’s 
ability to seek out aid along with the resources of a capable hospital. Cases are often underreported or 
dismissed due to lack of resouces.4 Recent outbreaks of ZIKV have been liked to mass travel for events 
like major sporting events and warmer temperatures for the host mosquitoes to thrive in.4  Currently, there 
are no designated, FDA approved antivirals or vaccines on the market against ZIKV which means 
supportive care is the best option against mild to severe symptoms.9 Majority of efforts to slow spread 
revolve around education on abstinence from sexual intercourse or barrier protection for 6 months 
however a common antiviral, ribavirin has recently indicated some promise as a potential treatment 
option in the future.9,10  
 
1.6 Dengue Virus 
 Another virus that is transmitted via Aedes mosquitoes is dengue (DENV). Like most viruses, 
there are neither vaccines nor effective FDA approved therapies against dengue. As a result doctors to 
simply manage the symptoms of those infected.11,12 Often characterized by the virus serotypes 1 through 5 
(DENV-1 to DENV-5), infection from DENV does not always yield symptoms.13,14 Symptomatic 
infections of the virus range from mild as in dengue fever (DF), to severe forms which are referred to as 
dengue hemorrhagic fever (DHF) which can progress to dengue shock syndrome (DSS).13  DENV has a 
long history in the Americas dating back to 1600’s. Recent outbreaks of dengue in the United States in 
Florida, Texas and Hawaii have been noted to be sources of local spreading of this disease marking the 
fact that this is no longer a travel-associated disease.15 However, most outbreaks of this virus follow an 
endemo-epidemic pattern that yields outbreaks approximately every 3 to 5 years.13 These outbreaks are 
often characterized by a temporary, larger than normal increase of cases due to various factors to include 
weather and lifestyle patterns. The CDC estimates that 40% of the world’s population live in areas where 
dengue is prevalent.15 With a vast portion of the world’s population at risk the need for targeted therapies 








NANOPARTICLE DESIGN AND APPROACH 
 
 The rise in disease carrying mosquitoes in urban areas sheds light on an issues that researchers 
have put limited efforts in. The need for targeted treatments for antivirals is clear but the response is 
lacking. An answer to this growing problem is to create a nanoparticle system that carries known 
antivirals to the locations inside the cell that viruses replicate in. By utilizing the micro pH values found 
in cells, a drug delivery system can be modified in order to carry the antivirals directly to where the 
viruses are found thus in theory having greater overall success in stopping replication. This approach 
requires synthesis of a biocompatible polymer capable of being turned into a tunable nanoparticle system 
that is successful in encapsulating and releasing the antiviral on demand.  
  
2.1 Introduction of Biodegradable Coblock Polymers 
 The use of biodegradable polymers in biomedical applications has recently become a center of 
interest due to their wide range of applications.16-19  Unique properties allow scientists to assemble these 
medically safe polymers into functioning nano-sized units, increasing the pharmacological applications of 
biocompatible polymers.18,19 These biodegradable polymers are broken down, absorbed or eliminated in a 
human body shortly after their purpose has been fulfilled, making them desirable in biomedical 
applications.20 Often biodegradable co-block polymers are utilized in fabrication of biomaterials, which 
refers to natural and/or synthetic substances that are engineered to interact specifically with biological 
systems in order to direct medical treatment.20  This is due to the fact that they do not require removal or 
special handling in order to meet long-term safety requirements. In theory, biodegradable polymers 
degrade at a rate that is approximately equal to the healing or regeneration processes of the body in which 
they are designed to aid. 20 The degradation of the polymer products also are nontoxic, metabolized, and 
excreted easily, therefore making biodegradable co-block polymers the sensible choice for countless 
environmentally friendly and biomedical applications.16-20 
 Biodegradable co-block polymers in drug formulation is a multifaceted endeavor. Scientists 
merge biocompatible monomers that are specifically chosen for advantageous properties, such as drug 
solubility and dissociation.16,17  Specifically arranged monomers or “blocks” combine into copolymers and 
allow scientists to explore the promising biomedical applications, to include drug delivery systems, since 
amphiphilic block copolymers have been noted to self-assemble to form polymeric micelles under certain 
concentrations.16 By selecting polymers with properties such as pH-responsive dissociation, thermal self-
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assembly or even hydrophobicity properties, a new era of tunable systems can emerge to increase 
selectivity and decrease toxicity.16-20 
 
2.2 Triblock mPEG-PCL-mPEG Polymer 
             The triblock, mPEG-PCL-mPEG is a solid candidate for biocompatible materials due to its pH-
responsive dissociation, thermal self-assembly and hydrophobicity properties.16,17,21 The polymer chain, 
mPEG-PCL-mPEG, gets its name 
from the three segments that are 
joined to form a single triblock strand: 
polyethylene glycol, poly(e-
caprolactone) and another 
polyethylene glycol. Polymer segment 
patterns are often shorthanded to 
alphabetic patterns that assign letters 
to each respective monomer unit. For 
the mPEG-PCL-mPEG triblock polymer the letters assigned would be, “ABA” since the end units are the 
same monomer. Here the “A” units refer 
to the polyethylene glycol or  PEG which 
caps the “B” unit of poly(e-caprolactone). 
The A monomer is coupled to the B 
monomer to form a diblock which is then 
capped with another A monomer in order to form the complete ABA triblock polymer (Figure 4). 
Polymerization of the ABA triblock occurs through two steps, open ring polymerization of the e-
caprolactone utaliziling polyetheylene glycol as the macro-initiator and stannous octoate as the catalast 
then combining the diblock through modification of the hydroxyl group of a polyetheylene glycol to a 
carboxylic acid in order to be conneceted to the previously formed diblock (Figure 5 & 6).16,17,21    
The synthesized triblock, mPEG-PCL-mPEG, is useful as a biomaterial due to its unique ability to 
undergo thermal induced self assembly without the need for harsh solvents along with its disociation 
point of a pH of 5.4, the pH of the late endosome.16,17,20 By strategically lining up under special thermal 
requirements, the solvent can remain 
biocompatable and with a disociation point 
revolving around a pH of 5.4 the polymer can 
target the acid-catalyzed fusion of virus and 
endosome where viral RNA is released and 
Figure 4. General scheme of an ABA triblock formation. 
H3C









Figure 5. AB diblock formation via ring-opening 














Figure 6. The reaction for PEG monomer formation 
to be coupled with the AB diblock.  
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initiated for replication in the ER.1-3,16,17,20 It is these advantageous biodegradable and nontoxic properties 
that make the ABA triblock polymer enticing as a possible drug delivery system.17 
 
2.3 mPEG-PCL-mPEG Micelles 
              Nanoparticles are currently pursued to enhance or replace older medical therapies due to their 
interesting and tunable properties.18 From image enhancing to antimicrobial effects to drug delivery 
systems, nanoparticle uses seem bound 
only by one’s imagination.18  Scientists 
find nanoparticles’ unique properties of 
selectivity, size, shape and 
biocompatibility allow for increased 
specificity, making them highly sought 
after in biomedical applications.18 
Biodegradable polymeric nanoparticles 
composed of segmented biocompatible 
polymers spark the interest of scientists 
due to their ability to form micelles/vesicles that can be optimized for their release under specific 
parameters.16 Polymeric micelles can be divided into two sections, the outer shell and their inner core 
(Figure 7). Scientists have determined that drug loaded micelles with an outer hydrophilic shell have 
bonus effects in the body, including increased circulation time of drugs, in vitro stabilization, and 
prevention of recognition by  macrophages post-intravenous injection.22 Polymer-based nanoparticles 
made from mPEG-PCL-mPEG create a hydrophilic bubble which allows for drug-loading of numerous 
polar molecules and when coupled with the known pH responsiveness of the system can be utilized in 
targeting key micro pH values important in viral reproduction (Table 1). By creating a bubble for the 
drugs to be loaded into common hurdles for drug development, water solubility for intravenous 
administration can be easily met without the need to alter the drug itself.23   
 
2.4 Thermal Induced Self-assembly of Polymeric Micelles 
 The amphiphilic block copolymers introduced in section 2.3 assemble under unique conditions. 
The copolymers can self-assemble into polymeric micelles in an aqueous solution, thus creating the 
perfect environment for hydrophobic drugs.16,23  Depending on the needs for the drug the inner core of the 
micelle can be designed to match the best environment for the drug, either hydrophilic or hydrophobic. 
While previous labs have used environments suited for redox reactions or solvent swaps in order to 




assemble and drug load their micelles, an issue arises in the purity, and can lead to increased cytotoxicity 
once the sample is finalized.16,19,23 The possibility of harsh organic solvents being left behind in solution 
leads to ethical questions of purity. A new method to form the micelles which aims to avoid these ethical 
topics is “thermal induced self-assembly”. Self-assembly of the polymeric micelles in this fashion 
revolves around the idea that the polymers display thermosensitivity and, thus, when exposed to a sharp 
transition in heat they tend to aggregate in an orderly manner thus forming spherical shells that can be 
utilized as a carrier (Figure 7).23  Since the only requirement for the formation of the micelles is the sharp 
transition of heat, the need for harsh solvents is eliminated, and the formation can be placed in a 






























DRUG-LOADING OF MICELLES 
 
3.1 Introduction to Drug-loading of Polymeric Micelles 
 The polymeric micelles discussed above are designed with one overarching goal in mind: to 
deliver the drug of choice into a specific region and then release it in a manner that is safe, effective, and 
efficient. The concept of a drug delivery system is not new, with the past 25 years seeing the bulk of 
research growth in biodegradable/biocompatible materials such as polymers.20,24,25 With the ability to 
yield high drug-loading capacity in relationship to relative size, nanomaterials composed of polymers can 
offer more than traditional methods of drug dosing.24 Higher specificity brought on by strict pH-specific 
dissociation results in higher accumulations of drugs at targeted locations. Since the reported average 
diameters of polymeric micelles ranging from 30-50 nm, close to the size of most viruses, the micelles are 
easily uptaken by the cell.23,24 Another benefit to the drug delivery system is that the polymer-based shell 
creates a protective cover over the drugs which results in the in vitro stabilization of the drug due to 
protection of this drug from various destructive agents found in the body.25 Simply put, the shell is 
thought to disguise the drug from the body’s protective mechanisms. With less drug required in order to 
effectively dose a patient, cytotoxicity concerns also decrease. There is a low risk of chronic 
accumulation in the body, especially when the polymer components used are considered biocompatible.25  
 Drug-loading of  polymeric micelles can be achieved through 3 common methods: direct 
dissolution, solvent evaporation, and dialysis.25 Depending on the solubility of the polymeric micelles and 
the drug, the most common methods are direct dissolution and solvent evaporation.16,19,23,25-27 In these 
methods, the polymer micelles are suspended in solvent (water for direct dissolution or an organic solvent 
for solvent evaporation) and occasionally subjected to temperature increases to enhance drug loading.23-26 
When the polymer blocks are long, i.e. more than 4 or 5 blocks and/or hydrophobic, the micelles do not 
drug-load easily and therefore require a different method, dialysis. In this method a solvent exchange 
occurs through the dialysis tubing which facilitates the exchange of water and drug in order to drug-load 
the micelle.25 This method is highly effective for larger micelle complexes.  However, this method tends 
to be a lengthy process since dialysis requires solvent adjustments in a timely manner.  
 The method utilized in drug-loading of the triblock polymeric micelles, such as mPEG-PCL-
mPEG, is based on direct dissolution and is referred to as “thermal induced self-assembly and loading” 
(Figure 6).23 This method is ideal for a few reasons, including lower risk of toxicity and speed of drug 
loading. Based on the concept that when micelles are suspended in a solvent in which the drug of choice 
is also suspended, the drug will “load” into the micelles to increase stability when subjected to a change 
in temperature.23,25-27  The use of heat coupled with sonication aids in drug loading to enhance output of 
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correctly formed micelles that encapsulate the drugs. 23,25-27  Since heat can drive the formation and drug 
loading of the micelles, the mPEG caps of the triblock employ an important role in this process.  During 
the thermal induced self-assembly and drug-loading, the ABA block polymer utilizes PEGylated ends to 
control the particle size and prevent aggregation over long periods of time.28 It has also been reported that 
the PEGylated lipid mimic acts as a temporary immune shield from the body’s defense system for the 
drugs.28 By utilizing only heat and sonication for the formation and drug-loading process, there is no fear 
of in vitro toxicity due to remnant organic solvents.  
 
Figure 8. General scheme of thermal induced self-assembly and drug-loading of ABA triblock-based 
micelles. Drug-loading of micelles is achieved when the polymer is heated to form the micelles. Then the 
drug of choice is added to the suspension just prior to sonication of the solution.  
  
3.2 Topological Polar Surface Area 
 Determination of the ideal amount of any drug to load into the micelles requires a unique 
approach in order to decrease wasted drug. Since drug carriers of various sorts have become wildly 
popular in recent years, the methods surrounding determining how much to drug load, along with how to 
drug load, has become almost overwhelming. 16,19,23,25-27  Researchers who conjugate the drug to the 
polymer itself have a vastly different approach than the researchers who free load the drugs onto the 
micelles and therefore the outcomes often vary.23,25,26,29 Another factor to consider is that antiviral drug 
properties/bioavailability is often not as easily accessible or researched as other drug candidates, such as 
cancer treatments. Previous uses for drug carriers on the market or in development are dominated by 
anticancer drugs.23,25,26 Lipid mimics or lipid nanoparticles have not been utilized as frequently with other 
drug candidates until recent years.29 This setback has recently been overcome with the development and 
widespread use of Moderna’s and Pfizer’s vaccines that target prevention of the disease COVID-19, 
which stems from infection of SARS-CoV-2.29 The vaccine which is a PEGylated lipid that houses 
mRNA of the virus is credited as the first widespread successful use of a lipid micelle.29 Since the vaccine 
is a recent achievement and therefore not an applicable tool on which to base any drug-loading, scientists 
had to adapt data from other sources in order to relate drug-loading of less common options such as 
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antivirals. It is no secret that cancer is the top funded research on any disease in the world.30,31 With just 
the United States budget in 2018 sitting at $5.94 billion it is easy to say that anticancer drugs are some of 
the most researched options for drug-loading into the micelles.31 Established concentrations of common 
anticancer drugs (e.g. doxorubicin) to load into specific coblock polymer micelles can be related to lesser 
studied drug candidates, like antivirals, in order to determine an ideal drug loading amount.23,25,26  
 To relate two different drugs for drug loading, a method called topological polar surface area can 
be used. Topological polar surface area or TPSA is a common descriptor that is defined as the sum of the 
surface of all the polar atoms in a given molecule.32,33 
TPSA is a modern method compared to its older 
counterpart, polar surface area (PSA), and TPSA, which 
specifically utilizes software that itemizes polar fragments 
of the drug compound then determines the individual PSA 
contributions in order to determine the molecule’s 
combined TPSA.32,33 TPSA allows for a quicker and 
simple method of calculating a molecule’s polar surface 
area when compared to PSA (Figure 9), due to the lack of 
3D structure which is traditionally required for software 
calculations of PSA.33 The tabulated total polar surface 
area, calculated via TPSA, allows for the direct 
comparison of drug loading capabilities of the well-
studied anticancer drug candidates to the lesser studied drug 
candidates such as antivirals.  
  
3.3 Introduction of the Antiviral, Ribavirin 
 The guanosine analog, ribavirin has become a long standing frontline antiviral due to its’ broad 
spectrum of antiviral activity (Figure 10).10,34-36 The 
mechanism of action for ribavirin is centered 
around its ability to function as a mutagen, thus 
increasing error catastrophe in replication.34 Since 
ribavirin has the ability to become incorporated into 
the viral RNA, it directly inhibits viral RNA 
synthesis and therefore induces viral genome 
mutations which ultimately lead to inhibition of 



















Figure 9. Comparison of determination 








Figure 10. Structure of the antiviral, ribavirin; 




settings of suppression for numerous viruses such as hepatitis C, respiratory syncytial virus, Lassa fever 
virus, dengue, and Zika viruses. However, ribavirin is currently only approved by the U.S. Food and Drug 
Administration for the treatment of hepatitis C infections.10,34,35,37   
 
3.4 Introduction of the Fluorescent Tracking Dye,  Nile Red 
 Nile red, or Nile blue A oxazone, is a 
photostable polarity-sensitive fluorescent probe that 
fluoresces intensely at 552 nm and can be utilized as a 
fluorescent stain for determination of intracellular 
uptake (Figure 11).10,38-41 This lipophilic fluorescent 
probe  is ideal for determining uptake and 
intracellular distribution due to its excitation at 
552nm and its ability to be drug-loaded into 
nanoparticles in a similar manner to the typical drug 
candidates.38-41 Commonly used as a histological dye, 
Nile red is easily adapted to function as a fluorescent probe in nanomaterials allowing scientists to study 
uptake and distribution with in vitro studies.39-41   
   
3.5 Introduction of the Antiviral, 6-Azauridine 
 The analogue of uridine, 6-Azauridine, is another common broad 
spectrum antiviral that is commonly tested alongside the previously 
mentioned antiviral, ribavirin (Figure 12).10,42-44 It has been reported that 
6-Azauridine has positive antiviral activities when tested in vitro against 
a minimum of 11 different pathogenetic Flavivirus viruses to include 
dengue and Zika. However, it should be noted that at this time, 6-
Azauridine has not been FDA approved of the treatment for any virus due 
to concerns about toxicity in significant quantites.42-44 This drug’s 
antiviral activity is attributed to increasing the levels of uridine kinase, 
which converts uridine to uridine monophosphate, a nucleotide used in 
viral RNA synthesis.43,44 While 6-azauridine can possess toxic effects in 
large amounts, in vitro studies have shown some antiviral properties with 




Figure 11. Structure of the fluorescent 
probe, Nile red; TPSA: 46.34 Å² 
Figure 12. Structure of the 
antiviral, 6-Azauridine; 




CHAPTER 4  
 
MATERIALS AND METHODS 
 
4.1 Synthesis of Triblock polymer, mPEG-PCL-mPEG 
 Synthesis of mPEG-PCL-mPEG triblock polymers occurs through coupling AB diblock 
copolymers with a capped A monomer. The chemicals for the AB diblock, poly(ethylene glycol) methyl 
ether or mPEG (CAS# 9004-74-4, Mn 5,000), were purchased from Aldrich, epsilon-Caprolactone or e-
caprolactone (CAS#502-44-3) and Tin(II) 2-ethylhexanoate or stannous octate (CAS#301-10-0) were 
purchased from Alfa Aesar, methylene chloride or dichloromethane (CAS#75-09-2) were purchased from 
Fisher Chemical, diethyl ether (CAS#60-29-7) were purchased from VWR, and hexane (CAS#110-54-3) 
was also purchased from Fisher Chemical. The chemicals to synthesize the capped A monomer, succinic 
anhydride (CAS# 108-30-5) was purchased from ACROS Organic, 1,4-dioxane (CAS#123-91-1) came 
from Fisher Chemical and 4-(Dimethylamino) pyridine (CAS# 1122-58-3) was purchased from Alfa 
Aesar. The chemicals to couple the AB diblock to the capped A monomer, 4-(Dimethylamino)pyridine 
(CAS# 1122-58-3), was purchased from Alfa Aesar, N,N’-Dicyclohexylcarbodiimide (CAS#538-75-0) 
was purchased from ACROS Organic, diethyl ether (CAS#60-29-7) was purchased from VWR and 
hexane (CAS#110-54-3) was purchased from Fisher Chemical. 
 To synthesize the mPEG-PCL-OH AB diblock, a ring-opening polymerization of e-caprolactone 
utilizing mPEG as a macro-initiator and stannous octate as catalyst occurs. Under a protective nitrogen 
atmosphere, 4mL of e-caprolactone, 2 g of mPEG and 100µL of stannous octate reflux at 130°C for 4 
hours. Once refluxed the solution is dissolved in dicholoromethane, then precipitated in 9:1 v/v 
concentration of chilled diethyl ether : hexane. The AB diblock polymer is then recovered and stored until 
the A monomer is completed. 
 To synthesize the capped A monomer, 0.2769 g of mPEG and 0.2001 g of succinic anhydride is 
allowed to react at room temperature in the presence of 3 mL of 1,4-dioxane and 0.0012 g of 4-
(Dimethylamino)pyridine for 24 hours. The reaction (Figure 3) yields the capped monomer, mPEG-
COOH, which is then ready to be coupled with the AB diblock, mPEG-PCL-OH. 
 The mPEG-PCL-OH based AB diblock is then coupled with the A monomer,  mPEG-COOH, via 
the addition of 0.00433 g of 4-(Dimethylamino)pyridine and 0.02933 g of N,N’-
Dicyclohexylcarbodiimide. This mixture is then allowed to react under the protection of nitrogen for 24 
hours, creating an ABA triblock polymer of mPEG-PCL-mPEG. The polymer is suspended in 1:1 v/v 
concentration of chilled diethyl ether : hexane and dialyzed (Fisherbrand regenerated cellulose dialysis 
tubing, nominal MWCO 12,000-14,000) against ultrapure DI water (18.2 MW.cm at 25°C) for 12 hours, 
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changing the water every 4 hours. The final solution is lyophilized (LABCONCO FreeZone 4.5 Plus) and 
stored at -20°C until characterization on Fourier-transform infrared spectroscopy (Thermo Scientific 
Nicolet iS10) or until further use. 
 
4.2 Synthesis of mPEG-PEC-mPEG Micelles 
 The ABA triblock polymer, consisting of mPEG-PCL-mPEG, can then be utilized to form blank 
micelles with an empty core. To synthesize blank micelles, the previously mentioned lyophilized mPEG-
PCL-mPEG triblock polymer is dissolved in ultrapure DI water (18.2 MW.cm at 25°C) at a ratio of 20 mg 
of polymer in 1 mL of water and placed in a water bath (Thermo Scientific Precision CIR 19) at 50°C for 
15 minutes, initiating thermal induced self-assembly of micelles. Once self-assembly is complete, the 
solution is filtered through a 0.2 µm syringe filter (Corning sterile syringe filter part no. 431215) and the 
filtrate containing blank micelles is characterized using UV-Visual spectroscopy (Shimadzu UV-2600 
UV-VIS Spectrophotometer) and dynamic light scattering (Malvern Nano series NANO-ZS ZetaSizer). 
 
4.3 Ribavirin Drug-loaded mPEG-PCL-mPEG Micelles 
 The amount of ribavirin needed to fully drug-load the sample was based on the molecules 
topological polar surface area or TPSA. Since TPSA is a common descriptor that is defined as the sum of 
the surface of all the polar atoms in a given molecule, ribavirin’s TPSA could be calculated and compared 
to the drug loading capacity of a known cancer drug, doxorubicin.32,33,36 Ribavirin’s TPSA was calculated 
via the software, Molinspiration Cheminformatics and was determined to be 143.73 Å².36 Doxorubicin’s 
TPSA was also calculated using the same software and was determined to be 206 Å².36 For doxorubicin’s 
drug loading capacity of 3 mg per 20 mg of triblock polymer, ribavirin is drug loaded at a rate of 4.5 mg 
per 20 mg of triblock polymer.  
 In order to drug-load the blank mPEG-PCL-mPEG micelles with ribavirin, 98% ribavirin was 
purchased from ACROS Organic (CAS#36791-04-5), and was combined with the blank micelle 
suspension at a ratio of 4.5mg of ribavirin per 1mL suspension of the previously suspended blanks in 
ultra-pure DI water (18.2 MW.cm at 25°C). The solution is sonicated in a Bransonic ultrasonic water bath 
(CPXH series) at 37°C for 30 minutes on high. Once finished the solution is then passed through a 0.2 µm 
syringe filter (Corning sterile syringe filter part no. 431215) to remove any ribavirin that aggregated 
instead of loading into the micelles. Final characterization of the micelles using UV-Vis spectroscopy 
(Shimadzu UV-2600 UV-VIS Spectrophotometer) and dynamic light scattering (Malvern Nano series 




4.4 Kinetics Study of Ribavirin-loaded mPEG-PCL-mPEG Micelles 
In order to create a ribavirin standard, 10 samples with concentrations from 0.025 g/3.5 mL to 
0.25 g/3.5 mL were created from a stock of 1 g/3.5 mL. The 98% ribavirin was purchased from ACROS 
Organic (CAS#36791-04-5) and dissolved in ultrapure DI water (18.2 MW.cm at 25°C). The stock and 
aliquots were suspended further in ultrapure DI water to create the various samples. The 10 samples 
comprising the ribavirin standards were then analyzed using UV-Vis spectroscopy (Shimadzu UV-2600 
UV-VIS Spectrophotometer) and a standard was determined at 270nm.  
The release of ribavirin from the triblock micelles occurred through dissociation of the micelles 
started by the change in pH. Ribavirin-loaded micelles were synthesized as mentioned in Section 4.3 and 
the pH was corrected via dropwise addition of phosphate buffer saline or PBS bought from Sigma-
Aldrich (Lot # D8537) until the pH was measured to be 5.49 using a Fisherbrand accumet benchtop pH 
meter. The sample was then analyzed using UV-Vis spectroscopy (Shimadzu UV-2600 UV-VIS 
Spectrophotometer) and dynamic light scattering (Malvern Nano series NANO-ZS ZetaSizer) for the 
remainder of the experiment.  
4.5 Nile Red Drug-loaded mPEG-PCL-mPEG Micelles 
The amount of Nile red needed to fully drug-load the sample was based on the molecule’s 
topological polar surface area or TPSA. Nile red’s TPSA could also be calculated and compared to the 
drug loading capacity of a known cancer drug, doxorubicin.16 Nile red’s TPSA was calculated via the 
software Molinspiration Cheminformatics, and was determined to be 46.34 Å².36 Doxorubicin’s TPSA 
was previously calculated using the same software and was determined to be 206 Å².36 Comparison of 
doxorubicin’s drug loading capacity to Nile red, doxorubicin can load 3mg per 20mg of triblock polymer 
while Nile red is able to drug load 0.5 mg per 20 mg of triblock polymer. 
In order to drug-load the blank mPEG-PCL-mPEG micelles with the fluorescent tracking dye, 
Nile red, was purchased from Tokyo Chemical Industry (CAS#7385-67-3), and was combined with the 
blank micelle suspension at a ratio of 0.5 mg of Nile red per 1 mL suspension of the previously suspended 
blanks. The solution was sonicated in a Bransonic ultrasonic bath (CPXH series) at 37°C for 30 minutes 
on high. Once finished the solution was then passed through a 0.2 µm syringe filter (Corning sterile 
syringe filter part no. 431215) to remove any Nile red that aggregated instead of loading into the micelles. 
Final characterization of the Nile red-loaded micelles was performed using UV-Visual spectroscopy 
(Shimadzu UV-2600 UV-VIS Spectrophotometer) and dynamic light scattering (Malvern Nano series 
NANO-ZS ZetaSizer) ensures that Nile red was correctly loaded into to nanoparticles. 
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4.6 6-Azauridine Drug-loaded mPEG-PCL-mPEG Micelles 
The amount of 6-azauridine needed to fully drug-load mPEG-PCL-mPEG micelles was based on 
the molecule’s topological polar surface area or TPSA. The 6-azauridine’s TPSA could also be calculated 
and compared to the drug loading capacity of a known cancer drug, doxorubicin.16 The 6-azauridine’s 
TPSA was calculated via the software Molinspiration Cheminformatics and was determined to be 132 
Å².36 Doxorubicin’s TPSA was previously calculated using the same software and was determined to be 
206 Å².36 For doxorubicin’s drug loading capacity of 3 mg per 20 mg of triblock polymer, 6-azauridine’s 
is able to drug load 4.9 mg per 20 mg of triblock polymer. 
In order to drug-load the blank mPEG-PCL-mPEG micelles with 6-azauridine, 6-azauridine was 
purchased from Biosynth Carbosynth (CAS#54-25-1), and is combined with the blank micelle suspension 
at a ratio of 4.9mg of ribavirin per 1mL suspension of the previously suspended blanks. The solution is 
sonicated in a Bransonic ultrasonic bath (CPXH series) at 37°C for 30 minutes on high. Once finished the 
solution is then passed through a 0.2 µm syringe filter (Corning sterile syringe filter part no. 431215) to 
remove any leftover 6-azauridine that aggregated instead of loading into the micelles. Final 
characterization of the micelles using UV-Visual spectroscopy (Shimadzu UV-2600 UV-VIS 
Spectrophotometer) and dynamic light scattering (Malvern Nano series NANO-ZS ZetaSizer) ensures that 
6-azauridine was correctly loaded into to nanoparticles.
4.7 Drug Release Study of 6-Azauridine Drug-loaded mPEG-PCL-mPEG Micelles 
The release of 6-azauridine from the triblock micelles occurred through dissociation of the 
micelles and was initiated through decreasing the pH in the cuvette. The 6-azauridine-loaded micelles 
were synthesized as described in Section 4.6 and the pH was corrected via dropwise addition of phosphate 
buffer saline or PBS bought from Sigma-Aldrich (Lot # D8537) until the pH was measured to be 5.74 
using a Fisherbrand accumet benchtop pH meter. The sample was then analyzed using UV-Vis 
spectroscopy (Shimadzu UV-2600 UV-VIS Spectrophotometer) and dynamic light scattering (Malvern 
Nano series NANO-ZS ZetaSizer) in order to ensure dissociation of the micelles.  
4.8 6-Azauridine Standard 
In order to create the 6-azauridine standard, 7 samples with concentrations ranging from 0.01 
g/mL to 0.1 g/mL were created from a 6-azauridine stock solution of 0.1 g/mL. The 6-azauridine was 
purchased from Biosynth Carbosynth (CAS#54-25-1), and dissolved in ultrapure DI water (18.2 MW.cm 
at 25°C) for the stock, and aliquots were suspended further in ultrapure DI water to create the various 
samples. The 7 samples were then analyzed by UV-Visual spectroscopy (Shimadzu UV-2600 UV-VIS 




5.1 Characterization of the Triblock, mPEG-PCL-mPEG 
The triblock polymer, mPEG-PCL-mPEG, was synthesized following a previously reported 
method.16 To ensure correct formation of the triblock, Fourier-transform infrared spectroscopy, or FTIR, 
was performed on the A monomer (mPEG) along with the full ABA triblock (Figure 13). FTIR peaks 
were compared to literature values in order to confirm the addition of the capped end onto the middle, 
diblock segment. The addition of the peak around 1700 cm-1 in the triblock polymer indicates the 
presence of the esters in the PCL segment, while the extra peak around 2900 cm-1 on the traditional broad 
OH peak is attributed to CH stretching found in the mPEG segments of both polymers and the addition of 
the small peak in the fingerprint region at 1100 cm-1 is the ether stretching.16  
Figure 13. FTIR analysis of the capped A monomer, mPEG-OH, alongside the complete triblock polymer, 
mPEG-PCL-mPEG. The complete polymer is shown stacked on top of the capped monomer.  
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5.2 Characterization of Ribavirin-loaded mPEG-PCL-mPEG Micelles 
Drug-loaded triblock micelles consisting of the copolymer, mPEG-PCL-mPEG, and the drug, 
ribavirin, were synthesized using thermal induced self-assembly and drug-loading. Polymer based 
micelles without any drugs loaded into them, called “blanks,” were synthesized initially and checked to 
ensure micelle formation occurred before moving on to drug loading. Figure 14 shows UV-visual 
spectroscopy spectra of the ribavirin-loaded micelles compared to the blank triblock micelles. Loaded 
mPEG-PCL-mPEG micelles have a broad peak that occurs at approximately 270 nm while the blanks are 
slightly red shifted and have a broad peak around 300 nm.  
Figure 14. UV-visual spectroscopy comparing ribavirin loaded along with blank mPEG-PCL-mPEG 
micelles suspended in ultra-pure DI water. 
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The drug-loaded micelles 
were further characterized in order to 
ensure overall quality. In order to 
predict major repulsive or attractive 
forces that could become an issue 
once the micelles are tested in vitro,  
micellar surface charge was measured 
via zeta potential and the average 
diameter of each micelle particle in 
suspension was calculated through 
dynamic light scattering. The zeta 
potential of  ribavirin-loaded mPEG-
PCL-mPEG micelles is -3.74 ± 0.675 
mV (Figure 15) while the average 
diameter of the micelles is 63.44 ± 
8.615 nm (Figure 16). It is significant 
to ensure the surface charge of the 
micelles is within ±30 mV in order to 
assume that the micelles will not experience any attractive or repulsive forces when tested in vitro.46 
Figure 15. Zeta potential of the mPEG-
PCL-mPEG micelles suspended in ultra-
pure DI water. 
Figure 16. Average diameter of the drug-loaded mPEG-PCL-mPEG micelles suspended in 
ultra-pure DI water determined by dynamic light scattering. 
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5.3 Kinetics Study of Ribavirin-loaded mPEG-PCL-mPEG Micelles 
 To test pH-responsive drug release, an initial kinetics study was performed on a standard of the 
drug ribavirin. A standard of 10 samples with varying amounts of ribavirin dissolved in 3.5mL of DI 
water was created by taking the UV-visual spectroscopy of the 10 samples and then comparing their 
absorbances at 270 nm to assess their concentration of drug in mg/mL (Figure 17 & 18). The samples 
showed enough separation at 270nm that a linear equation to determine concentration based on the 
absorbance could be reasonably assumed. The inlet on figure 17 at the top right is the portion of the 
spectrum (250nm-300nm) where the separation of each spectra occurs. The ribavirin-loaded samples  
are relatively unremarkable before and after that range with the greatest separation occurring at 270nm. 
The separation found at 270nm was plotted using the concentration and absorbance variances in order to 
produce the standard shown in figure 18. The linear separation found at 270nm yielded the equation that 
would be used in future determination of drug release. 
Figure 17. UV-Visual spectroscopy of varying concentrations from 0.025g/3.5mL to 0.25g/3.5mL of 
ribavirin in DI water. The inlet at the top right shows a closer look at the separation of the samples.  
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Second, a kinetics study involving the release of ribavirin from the triblock, mPEG-PCL-mPEG, 
was initiated with 1.5mL of ribavirin-loaded mPEG-PCL-mPEG micelles that were characterized prior to 
Figure 18. Standard created of ribavirin utilizing data from Figure 17 at 
270nm. 
Figure 19. UV-visual spectra of kinetics study to determine release of ribavirin. 
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and following pH adjustment to pH of 5.49, thus 
signifying the beginning of dissociation. These 
samples, were assessed by UV-visual spectroscopy 
in the wavelength range of  800nm to 200nm, 
coupled with dynamic light scattering to monitor 
the release of the drug (Figures 19 & 20, Table 2). 
The first UV-visual spectra obtained after 
dissociation occurred at the 6 minute mark and was 
the most rapid the sample could be pH corrected, 
measured, and assessed in the instrument. The 
sample showed a complete release of the ribavirin 
at that point (i.e. by 6 minutes).  However, the 
sample was analyzed for 11 more data points to 
track any changes that might occur. The initial 
average diameter of the drug-loaded micelles 
determined from run 0 was 58.94 ± 6.051 nm while 
runs 1-12 showed an increase in instability 
consistent  
with the concept of dissociation. The difference in 
absorbance from runs 1-12 was minimal, while the average diameter varied.  Taken together these results 
show that successful dissociation of mPEG-PCL-mPEG occurred at pH 5.49, leading to complete release 
of ribavirin from these micelles. This release of drug is significant because the pH of the late endosome is 












Figure 20. Average diameter of micelles in kinetics study as dissociation 
occurs after adjustment of pH values past a pH of 5.4. 
Table 2. Elapsed time of the sample for the kinetics 
study. 
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5.4 Characterization of Nile Red-loaded mPEG-PCL-mPEG Micelles 
Nile red-loaded micelles were synthesized and characterized similarly to their ribavirin 
counterparts. The sample was characterized using UV-vis spectroscopy along with dynamic light 
scattering in order to ensure that the particles were fully formed and similar to the ribavirin loaded 
micelles (Figure 21 & 22). The average diameter of the Nile red-loaded micelles was determined to be 
84.73 ± 54.16 nm using dynamic light scattering, thus keeping the micelle well within the limits of easily 
being uptaken by cells. 
Figure 21. UV-visual spectroscopy of the Nile red loaded and blank, triblock micelles. Both 
samples were suspended in ultra-pure DI water and analyzed under stable conditions. 
Figure 22. Average diameter of Nile-red loaded mPEG-PCL-mPEG micelles 
suspended in ultra-pure DI water. 
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5.5 Characterization of 6-Azauridine-loaded mPEG-PCL-mPEG Micelles 
Triblock, mPEG-PCL-mPEG micelles were synthesized once again. Instead of loading with 
ribavirin, however they were loaded with the potential anti-Zika virus drug, 6-azauridine. The sample was 
characterized using UV-visual spectroscopy coupled with dynamic light scattering in order to ensure that 
the micelles were fully formed and similar to the original ribavirin-loaded micelles (Figures 23 & 24). 
The peak absorbance for the 6-azauridine-loaded micelles was slightly red-shifted and was closer to 300 
nm in emission while the average diameter of the 6-azauridine-loaded triblock micelles was determined to 
be 55.25 ± 23.90 nm, as shown by dynamic light scattering.   
Figure 23. UV-visual spectrum of 6-azauridine-loaded mPEG-PCL-mPEG micelles 
suspended in ultra-pure DI water. 
Figure 24. Average diameter of 6-azauridine-loaded mPEG-PCL-mPEG 




5.6 Drug Release Study of 6-Azauridine-loaded mPEG-PCL-mPEG Micelles 
 The 6-azauridine-loaded micelles were tested in a similar method to the ribavirin-loaded mPEG-
PCL-mPEG micelles to ensure drug release via pH correction. Once corrected to a pH over 5.4 the 
micelles begin to dissociate and are monitored using UV-visual spectroscopy coupled with dynamic light 
scattering to ensure dissociation (Figure 25 & 26). The absorbance decreased, which is consistent with 
drug release, and the average diameter of the 6-azauridine-loaded mPEG-PCL-mPEG micelles after 
dissociation increased and was determined to be 76.88 ± 17.16 nm using dynamic light scattering.  
Figure 25. UV-visual spectra of 6-azauridine-loaded and dissociated mPEG-PCL-mPEG micelles 
suspended in ultra-pure DI water. 
 
Figure 26. Average diameter of 6-azauridine-loaded mPEG-PCL-mPEG micelles 
suspended in ultra-pure DI water, after dissociation via a change in pH, determined by 




 A standard of 6-azauridine was created using a similar method to ribavirin’s standard. Varying 
concentrations of the drug, 6-azauridine was dissolved in DI water to achieve specific concentrations of 6-
azauridine in g/mL. The samples had UV-Visual spectra collected to determine the best wavelength for a 
standard and the determined wavelength used to gather absorbances in order to create a standard at 317 




















Figure 27. UV-Visual spectroscopy of varying concentrations of 6-azauridine ranging 
from 0.1g/mL to 0.075 g/mL suspended in ultra-pure DI water. 




Micelles made from co-block biodegradable polymers have a specific goal in mind, to deliver the 
drug of choice into a specific region then release it in a manner that is safe, effective, and efficient. This 
might sound similar to other nanoparticle drug delivery options, such as liposomes, however micelles 
preform their job differently. Micelles consist of a single layer of a lipid or lipid mimic while liposomes 
consist of a bilayer or two layers of the same lipid/lipid mimic.45 The single layer in micelles is important 
to their ability to undergo pH dissociation, thus releasing their payload under optimal circumstances. By 
creating a system that is pH dependent the micro pH values found inside cells can be targeted, thus 
decreasing the amount of required drug. The concept of a drug carrier based on pH responsive lipid 
mimics is a relatively novel field with limited research revolving around anticancer drugs and targeting 
micro pH values of cancer cells.16,23,32,33,36,44 With no previous work published on antivirals being drug-
loaded into micelles that are lipid or lipid mimics the research presented is the purest form of a novel 
concept.  
To synthesize the pH dependent micelles, first the biocompatible polymer capable of being 
formed into a drug carrier had to be made. The ABA, triblock polymer, mPEG-PCL-mPEG was 
synthesized following a previously reported method.16 While the previous lab have determined the pH 
dissociation and biocompatibility of the polymer, they were focused on using it as an anticancer drug 
carrier and thus had a different use for their system. In order to make the complete polymer, the A 
monomer consisting of mPEG or polyetheylene glycol was coupled to the B monomer, poly(e-
caprolactone), to form the AB diblock. The AB diblock was then capped with another of the same A 
monomer through polymerization in order to form the complete ABA triblock polymer. Once synthizised 
the polymer underwent characterization to ensure correct formation of the triblock. Fourier-transform 
infrared spectroscopy was run and analyzed on the A monomer along with the full ABA triblock (Figure 
13). 
The FTIR peaks and unique fingerprint regions were compared to literature values in order to 
confirm the correct polymerization occurred with the triblock. Since the polymer itself was not novel 
literature was able to provide insist on the fingerprint region and the key peaks found. The addition of the 
peak around 1700 cm-1 in the mPEG-PCL-mPEG sample indicates the presence of the esters in the 
middle, PCL segment. The additional peak around 2900 cm-1 on the traditional broad OH peak is 
attributed to CH stretching found in the mPEG segments of both polymers and the addition of the small 
peak in the fingerprint region at 1100cm-1 is the ether stretching.16 With the unique FTIR spectra’s 
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compared to literature values, the identity of the polymer could be confirmed as mPEG-PCL-mPEG and 
further experiments ensued.  
 With polymer successfully synthesized the next step was to pursue the synthesis of the 
nanoparticles. The nanoparticle, drug delivery system used was a single layer micelle made from a 
triblock polymer capable of dissociation at a specific pH value of 5.4. Triblock, biodegradable micelles 
made from mPEG-PCL-mPEG were synthesized, characterized and drug-loaded with ribavirin, Nile red, 
and 6-azauridne. The drugs ribavirin and 6-azauridine were selected for their previous success in 
literature as possible antivirals against common blood borne pathogens like Zika and dengue virus.10,34-
36,42-44  Since the system itself was novel the idea was to start out with known drug candidates to be able to 
ensure effectiveness of the drug delivery system. The other molecule Nile red was selected as a tracking 
dye and therefore yielded the capability of future experiments aimed at analyzing the cellular uptake of 
the micelles. 
  To synthesize the drug-loaded micelles, first polymer-based micelles without any drugs loaded 
into them called blanks were synthesized. The concept of turning polymers into micelles is not novel and 
thus various methods could have been pursued. For the purpose of creating a drug carrier that was 
biocompatible the method selected was thermal induced self-assembly. This method ensured the micelles 
were not suspended in a toxic solvent but rather were suspended in and drug loaded in ultra-pure DI 
water. Once formed, the blank micelles were checked to ensure micelle formation via UV-vis 
spectroscopy and dynamic light scattering before moving on to drug loading. In order to determine the 
corresponding amount of required drug to efficiently drug-load the micelles, topological polar surface 
area (TPSA) was run on the three molecules ribavirin, Nile red, and 6-azauridine.  
 Ribavirin’s TPSA was calculated via the software, Molinspiration Cheminformatics and was 
determined to be 143.73 Å².36 The calculated TPSA was compared directly to a known cancer drug, 
doxorubicin, in which the drug loading capacity was known for the triblock micelles.32,33,36 Since 
doxorubicin’s TPSA was 206 Å² and had a known drug loading capacity of 3 mg per 20 mg of triblock 
polymer, ribavirin’s drug loading capacity could be determined to load at a rate of 4.5 mg per 20 mg of 
triblock polymer 36. The blanks were used in drug-loading with the drug, ribavirin, and the loaded 
micelles were characterized using UV-vis spectroscopy and dynamic light scattering. Results showed the 
trend that ribavirin-loaded micelles, when compared to the blank micelles, are slightly shifted. The loaded 
micelles have a broad peak that occurs around 270 nm, while the blanks are slightly red-shifted and have 
a broad peak around 300 nm (Figure 14). The slight shift in these peaks is attributed to the loading of 
ribavirin, which is not found solely inside the micelle. Some of the drug can become trapped in the 
polymer layer, causing the peak to shift closer to the peak of the drug, ribavirin.  The ribavirin-loaded 
micelles were further characterized to ensure the overall quality. In order to predict major repulsive or 
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attractive forces that could become an issue once the micelles are tested in vitro, the surface charge of 
these micelles was measured via zeta potential and the average diameter of the micelle suspension was 
calculated through dynamic light scattering. The zeta potential of the mPEG-PCL-mPEG, ribavirin-
loaded micelles is -3.74 ± 0.675 mV (Figure 15) while the average diameter of the micelles is 63.44 ± 
8.615 nm (Figure 16). Since the surface charge of the micelles is within ±30 mV, it can be assumed that 
the micelles will not experience any attractive or repulsive forces when tested in vitro.46 The micelles’ 
average diameter, which is consistently around 60 nm, is also consistent with literature’s reported value of 
58 nm.23 With the near-neutral surface charge and the small average diameter below the upper limits of 
cellular uptake the drug loaded micelles meet all requirements noted in literature to be able to successfully 
preform the task of drug deliver to their target.  
With drug loading and characterization successful, the ribavirin-loaded micelles were next tested 
to ensure pH-responsive dissociation and drug release. Up until this point the micelles had only been 
tested to ensure characterization in order to meet the theoretical requirements to be able to deliver an 
antiviral to its target. Before assessing drug release, standards of ribavirin comprised of 10 different 
concentrations, each dissolved in 3.5 mL of DI water, were analyzed using UV-vis spectroscopy (Figure 
17). The samples indicated a linear separation of absorbances at 270 nm, as seen in the graph inlet on 
Figure 17, which was used to create a standard of drug concentration in mg/mL compared to their 
respected absorbances (Figure 18).  The kinetics study assessing the release of ribavirin from the triblock 
micelle comprised of mPEG-PCL-mPEG polymers consisted of a 1.5 mL sample of ribavirin-loaded 
mPEG-PCL-mPEG micelles that was initially characterized to ensure proper formation prior to 
assessment of micellar dissociation and subsequent drug release at pH 5.49 by drop wise addition of PBS. 
Once micellar dissociation started, the samples were assessed by UV-visual spectroscopy in the 
wavelength range from 800 nm-200 nm, coupled with dynamic light scattering to monitor the release of 
the drug (Figures 19 & 20, Table 2). The first UV-vis spectrum obtained after micelle dissociation was 
labeled “run 1” and occurred at the 6 minute mark. This was the quickest the sample could be pH 
corrected via dropwise addition, measured and analyzed in the instrument. The UV-vis spectrum obtained 
for this sample was compared to the spectrum of the initial drug loaded micelles, as indicated by run 0, 
and showed a complete release of the ribavirin by 6 minutes post-pH decrease to 5.49. The release of the 
drug yielded a slight blue-shift in the spectrum which was consistent in the kinetics study for the next 11 
data points. The initial average diameter of the drug-loaded micelles determined from run 0 was 58.94 ± 
6.051 nm while runs 1-12 showed an increase in instability indicated through the increase in standard 
deviation. The increase in instability is consistent with the concept of dissociation, since as the micelles 
begin to break apart their average diameter fluctuated, leading to the varying standard deviations. Since 
the difference in absorbance on the UV-vis spectra from runs 1-12 was minimum while the average 
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diameter varied, it is determined that this information collectively shows the occurrence of successful 
micelle dissociation and drug release. Now that the micelles had proven capable of the complete 
dissociation mediated by pH thus releasing the pay load, the other two molecules Nile red and 6-
azauridine could be drug loaded.  
 The triblock mPEG-PCL-mPEG micelles were next loaded with the fluorescent dye, Nile red. 
Nile red-loaded micelles were synthesized and characterized similarly to their ribavirin-loaded micelle 
counterparts previously described. Nile red’s TPSA was also calculated via the software Molinspiration 
Cheminformatics, and was determined to be 46.34 Å².36 Nile red’s TPSA was directly compared to the 
previously determined doxorubicin’s TPSA and drug loading capacity of 206 Å² and 3 mg per 20 mg of 
triblock polymer.36 From the comparison, Nile red was able to drug load 0.5 mg per 20 mg of triblock 
polymer. The Nile red-based sample was characterized once formed using UV-vis spectroscopy coupled 
with dynamic light scattering in order to ensure that the particles were loaded correctly and similar in size 
to the ribavirin loaded micelles (Figures 21 & 22). The average diameter of the Nile red-loaded micelles 
was determined to be 84.73 ± 54.16 nm using dynamic light scattering, which was larger than the 
ribavirin-loaded micelles yet still within acceptable range to ensure the ability of cellular uptake.47 The 
Nile red loaded micelles still met the theoretical requirements and were capable of pH mediated drug 
release like their ribavirin counterparts.  
 With both Nile red and ribavirin both successful in drug loading the last molecule 6-azauridine 
was ready to be drug loaded. Triblock, mPEG-PCL-mPEG blank micelles were synthesized once again 
for drug loading and characterized. However instead of loading with ribavirin or Nile red, they were 
loaded with the other drug candidate, 6-azauridine. The 6-azauridine’s TPSA was also calculated via the 
software Molinspiration Cheminformatics and determined to be 132 Å².36 This was compared back to 
doxorubicin’s TPSA of 206 Å² along with doxorubicin’s drug loading capacity of 3 mg per 20 mg of 
triblock polymer.36 For 6-azauridine, the drug loading capacity was 4.9mg per 20mg of triblock polymer. 
The 6-azauridine-loaded sample was characterized using UV-vis spectroscopy along with dynamic  light  
scattering in order to ensure that the micelles were fully formed and similar to the original ribavirin-
loaded micelles previously characterized (Figures 23 & 24). The peak absorbance on the UV-vis spectra 
for the 6-azauridine-loaded micelles was slightly red-shifted and was closer to 300 nm while the average 
diameter of the 6-azauridine-loaded triblock micelles was determined to be 55.25 ± 23.90 nm using 
dynamic light scattering. The slight red-shift was attributed to the loading of 6-azaurdine which is not 
found solely inside the micelle and thus causes the slight absorbance shift. The 6-azauridine micelles’ 
average diameter was once again similar to ribavirin-loaded micelles, and also well under the expected 
size limit for cellular uptake.23,47 With the micelles loaded with 6-azauridine meeting the theoretical 
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limitations for drug loading and cellular uptake the drug delivery system had the last main piece ready to 
be further tested for drug release. 
 After the 6-azauridine-loaded micelles were characterized using UV-vis spectroscopy along with 
dynamic light scattering and found to have similar characteristics to ribavirin-loaded micelles, the 6-
azauridine-loaded micelles were tested in a similar kinetic method in order to ensure similar drug release 
via pH correction. To test this the 6-azauridine-loaded micelles were corrected to a pH of 5.74 which is 
past their documented pH dissociation value and the dissociation was monitored using UV-visual 
spectroscopy along with dynamic light scattering to ensure proper release of the drug (Figures 25 & 26). 
The absorbance decreased across the spectra, which is consistent with drug release as also indicated by 
the ribavirin-loaded micelles. The average diameter of the 6-azauridine-loaded mPEG-PCL-mPEG 
micelles following dissociation increased to a size of 76.88 ± 17.16 nm, as judged by dynamic light 
scattering. Similarly, this increase in average diameter matches the increase noted in the ribavirin-loaded 
micelles and is consistent with the idea that as the micelles begin to dissociate, they swell and/or collapse, 
causing a wider range of average diameters.  
 In a fashion similar to the construction and assessment of the ribavirin standards, 7 concentrations 
of 6-azauridine standards were produced. Varying concentrations of the drug, 6-azauridine, were 
dissolved in DI water to achieve specific concentrations of 6-azauridine, in g/mL, and the samples were 
used to collect UV-vis spectra to determine the best wavelength for a linear standard. The samples 
indicated a linear separation at 317 nm and therefore the absorbance at 317 nm was used to relate drug 
release of 6-azauridine in g/mL (Figures 27 & 28)  This method mirrored the previous method and set the 
ground work for future experiments possible looking into precise drug release amounts.  
 The micelles themselves follow some basic trends when working with them as a whole. First, 
there is a notable shift when drug loading the blank micelles. The blanks when compared to the drug 
loaded are consistently red shifted. This phenomenon is attributed to imperfect drug loading of the 
micelles since when forming, the drug of choice does not perfectly load into the center and small amounts 
are trapped in the polymer layer. These small amounts of drugs have different light absorbances which 
shift the overall spectra slightly. The pattern of having a shift on the UV-vis spectra were consistent 
throughout the three options but the shift itself is dependent on the drug that is loaded. Another pattern 
noted though out the three options is that blank micelles and their dissociated counterparts are not overly 
stable in nature. The polymer based micelles prefer to be stabilized with a drug loaded into it and while 
the core is not bonded to the polymer in any fashion there are weak intermolecular forces that stabilized 
the micelles making them more likely to be stable over long periods of time. The evidence for their lack 
of stability is clear throughout the dynamic light scattering data for each set of micelles. The average 
diameter data shows an increase in standard deviation that is consistent throughout the samples that do not 
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have anything loaded into their core while the micelles that are stabilized with a molecule loaded into it 
yield relatively small deviation and tend to be more consistent.   
The trends noted laid the foundation for a drug delivery system that is tunable to meet the 
demands of a wide range of applications against viruses. While the triblock, mPEG-PCL-mPEG polymer 
was specifically utilized to meet the pH dissociation of 5.4, there are endless options in coblock polymers 
that can be explored using this foundation of experiments to determine the capability of the system. 
Polymers can be selected for varying pH dissociation, time release, ability to be functionalized or even 
varied in size to meet the demands of loading larger/smaller or charged molecules. 16,19,23-27 The 
nanoparticle system is not defined by a single polymer, target or payload making it the launch point for a 
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The way scientists approach viruses has evolved greatly since the initial discovery of yellow fever 
virus over 100 years ago. As technology boomed, detection of infectious agents along with their 
identification paved the way for a new classification system able to adequately distinguish and categorize 
the various viruses discovered. Viruses could be grouped together based on similar properties and thus 
scientists began to research new methods against them accordingly. The recent increases in global 
temperature paired with the rise in travel has created new environments for common vectors such as the 
Aedes mosquitoes that now can thrive in a larger portions of the world. In Georgia, the increase in global 
temperature and urban travel has resulted in the conformation of the presence of Aedes mosquitoes in 
Georgia as early as 2016, specifically the Aedes aegypti.6 The emergence of these mosquitoes has come 
with the challenge of dealing with viral transmission since mosquito-borne viruses of the Flaviviridae 
family, such as Zika virus and dengue, often utilize the Ades mosquitoes for transmittance.4,5 With no 
FDA approved therapies or vaccines against mosquito-borne pathogens, treatment and care for people 
infected with viruses like Zika and dengue revolve around a doctor’s ability to offer supportive care.9,11,12 
The need for research against selective therapies to target blood-borne pathogens is rapidly growing. The 
recent explosion of bio-based polymer research has become an unusual answer to the challenge of 
creating highly selective drug delivery methods.20 By combining pH sensitive, biocompatible polymers 
with common drugs known to have some antiviral properties, scientists are able to create drug carriers 
that release their cargo at locations in the cell that are key in the life cycle of specific viruses based on the 
cells’ micro pH (Table 1). Targeting cellular micro pH values with polymers that dissociate at a specific 
pH allow for creation of a drug delivery system that can be modified depending on the target subcellular 
location.  
With the target location of this thesis project revolving around the late endosome, a pH sensitive, 
drug delivery system needed to be created that could carry specific antivirals to the desired subcellular  
location and release them to interfere with the replication of the viruses’ life cycle. The biocompatible 
triblock polymer, mPEG-PCL-mPEG was selected based on its ability to form micelles and have a 
dissociation point of pH 5.4, thus making it a suitable drug delivery method that had the potential to target 
the late endosome. These micelles could be synthesized using methods that invoked minimal or no undue 
toxicity to the cells via thermal induced self-assembly and drug-loading.23-27 The drug-loaded micelles 
from the triblock polymer were synthesized and then seamlessly characterized to ensure quality and 
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overall uniformity across the two drugs analyzed: ribavirin and 6-azauridine, along with the fluorescent 
dye, Nile red. The micelles were kept below the maximum allowable  size to be easily uptaken by cells 
and studied to ensure proper release of their antiviral cargo at the appropriate pH change.16,17,47 Successful 
formation, encapsulation and dissociation of the micelles, was monitored via UV-Vis spectroscopy and 
dynamic light scattering. Drug release of the micelles was compared to their corresponding drug standard 
to determine full dissociation and kinetics of the polymer dissociation.  
With preliminary data to support the successful synthesis of ribavirin-loaded mPEG-PCL-mPEG 
micelles, future work will largely focus on other drug opportunities and testing the concepts in vitro. The 
concept of targeting cellular locations for drug release utilizing the specific pH dissociation of the 
polymer-based micelles, thus resulting in virus suppression, is ready to be investigated fully via in vitro 
studies. The micelles will be tested against JEG-3 (placental cancer cells), HMC3 (microglia cells), and 
Huh7 cells (liver cells) with and without infection. The cell lines JEG-3 and HMC3 cells will handle 
infection with Zika virus studies while Huh7 cells will be infected with dengue virus. Final analysis of the 
system will be geared towards infection of A129 mice which are immunodeficient mice that can be 
utilized in virus studies for dengue and Zika virus pathogenesis.  
Viral infection of various cells to determine the suppression ability of mPEG-PCL-mPEG must 
be carefully inspected with and without drug-loaded micelles. The overall toxicity of the micelles which 
has been reported in a general manner will have to be addressed using toxicity assays such as MTT assays 
to ensure the safety of the system. Further experiments aimed at targeting organelles in the cell with 
peptides such as the -KDEL peptide can also be pursued to gain a complete picture of how the drug 
delivery system works. It should also be noted that this is the ground work for a system that is tunable in 
order to fit numerous antiviral candidates along with variances in coblock polymers in order to target 
different micro pH’s using micelles that have other dissociation points.  The possibilities of the 
biocompatible coblock drug delivery system are not limited to mPEG-PCL-mPEG and the two antivirals; 
ribavirin and 6-azauridine, but rather is just beginning with the previous work acting as a foundation for 
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